Product List of Pharmaceutical
As a specialized, R&D-centered operation, the development of new world-class drugs is advanced to offer innovative and unique therapeutic solutions in the fields of orthopedics, critical/intensive care, urology, the immune system, and the central nervous system. September 2026, the main pharmaceutical operations in the U.S. and Europe adopted the unified brand of Asahi Kasei Therapeutics.
primary
Prescription drugs
default
2
Envarsus XR® (tacrolimus extended-release tablets)
Tarpeyo® (budesonide) delayed release capules
spacer
spacer
default
3
TERIBONE™ (teriparatide acetate)
Teribone™ is a human parathyroid hormone preparation that facilitates bone formation, for the indication of osteoporosis with weekly or twice weekly subcutaneous injections.
RECLAST™ (zoledronic acid)
Reclast™ is a bisphosphonate agent that suppresses bone resorption, for the treatment of osteoporosis with once-a-year intravenous infusion. Reclast™ is a registered trademark of Novartis.
RECOMODULIN™ (thrombomodulin alpha)
Recomodulin™ is a thrombomodulin agent produced through genetic engineering, indicated for the treatment of disseminated intravascular coagulation (DIC) associated with malignant tumors, infectious diseases, etc.
KEVZARA® (sarilumab)
Kevzara® is a human monoclonal antibody that blocks the action of IL-6, for the treatment of rheumatoid arthritis. Kevzara® is a registered trademark of Sanofi Biotechnology.
PLAQUENIL® (hydroxychloroquine sulfate)
Plaquenil® is an immunomodulator indicated for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Plaquenil® is a registered trademark of Sanofi-Aventis U.S.
DOPTELET® (avatrombopag maleate)
Doptelet® is a thrombopoietin receptor agonist, which is an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure. Asahi Kasei Therapeutics obtained exclusive distribution rights in Japan for Doptelet® for thrombocytopenia associated with chronic liver disease from Swedish Orphan Biovitrum Japan Co., Ltd.
CRESEMBA™（isavuconazonium sulfate）
Cresemba™ is an azole antifungal drug for fungal infections, such as Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), Mucormycosis, and Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis (including cryptococcal meningitis))
EMPAVELI® (pegcetacoplan)
Empaveli® is a PEGylated peptide1 inhibiting the function of complement protein C3 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Asahi Kasei Therapeutics obtained exclusive distribution rights in Japan for Empaveli® for PNH from Swedish Orphan Biovitrum Japan Co., Ltd.
spacer
For information on our pharmaceutical business in the United States and Europe, please visit the websites of Asahi Kasei Therapeutics Inc. and Calliditas Therapeutics AB.
button
2
Asahi Kasei Therapeutics Inc. website (External Link)
Calliditas Therapeutics AB website (External Link)
spacer